Autoimmunity-mediated antitumor immunity: Tumor as an immunoprivileged self

European Journal of Immunology

Volumn 42, Issue 10, 2012, Pages 2584-2596

  Miska, Jason ^a   Bas, Esperanza ^a   Devarajan, Priyadharshini ^a   Chen, Zhibin ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Autoimmunity; Cancer; CTLA4; Immunoprivilege; Treg cell

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BREAST CANCER; CELL THERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SELF ANTIGEN SPECIFIC EFFECTOR T CELL; TUMOR CELL; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIBODIES, BLOCKING; ANTIGENS, NEOPLASM; AUTOANTIGENS; AUTOIMMUNITY; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; CTLA-4 ANTIGEN; FEMALE; HUMANS; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE; LYMPHOMA; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; RNA, SMALL INTERFERING; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TUMOR MICROENVIRONMENT;

EID: 84867209754     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201242590     Document Type: Article

References (47)

1. Caspi, R. R., Immunotherapy of autoimmunity and cancer: the penalty for success. Nat. Rev. Immunol. 2008. 8: 970-976.
2. Gilboa, E., The risk of autoimmunity associated with tumor immunotherapy. Nat. Immunol. 2001. 2: 789-792.
3. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010. 363: 711-723.
4. Atkins, M. B., Mier, J. W., Parkinson, D. R., Gould, J. A., Berkman, E. M. and Kaplan, M. M., Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. 1988. 318: 1557-1563.
5. Gogas, H., Ioannovich, J., Dafni, U., Stavropoulou-Giokas, C., Frangia, K., Tsoutsos, D., Panagiotou, P. et al., Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 2006. 354: 709-718.
6. Fong, L. and Small, E. J., Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J. Clin. Oncol. 2008. 26: 5275-5283.
7. Sondak, V. K., Immunotherapy for melanoma: time for a new paradigm? The ASCO Post 2010. 3-4.
8. Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T. et al., CTLA-4 control over Foxp3 +regulatory T-cell function. Science 2008. 322: 271-275.
9. Ise, W., Kohyama, M., Nutsch, K. M., Lee, H. M., Suri, A., Unanue, E. R., Murphy, T. L. et al., CTLA-4 suppresses the pathogenicity of self antigen-specific T cells by cell-intrinsic and cell-extrinsic mechanisms. Nat. Immunol. 2010. 11: 129-135.
10. Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J. and Allison, J. P., Blockade of CTLA-4 on both effector and regulatory T-cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 2009. 206: 1717-1725.
11. Ligers, A., Teleshova, N., Masterman, T., Huang, W. X. and Hillert, J., CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun. 2001. 2: 145-152.
12. Wang, X. B., Zhao, X., Giscombe, R. and Lefvert, A. K., A CTLA-4 gene polymorphism at position -318 in the promoter region affects the expression of protein. Genes Immun. 2002. 3: 233-234.
13. Anjos, S., Nguyen, A., Ounissi-Benkalha, H., Tessier, M. C. and Polychronakos, C., A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele. J. Biol. Chem. 2002. 277: 46478-46486.
14. Kristiansen, O. P., Larsen, Z. M. and Pociot, F., CTLA-4 in autoimmune diseases-a general susceptibility gene to autoimmunity? Genes Immun. 2000. 1: 170-184.
15. Teft, W. A., Kirchhof, M. G. and Madrenas, J., A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 2006. 24: 65-97.
16. Monne, M., Piras, G., Palmas, A., Arru, L., Murineddu, M., Latte, G., Noli, A. et al., Cytotoxic T-lymphocyte antigen-4 (CTLA-4) gene polymorphism and susceptibility to non-Hodgkin's lymphoma. Am. J. Hematol. 2004. 76: 14-18.
17. Welsh, M. M., Applebaum, K. M., Spencer, S. K., Perry, A. E., Karagas, M. R. and Nelson, H. H., CTLA4 variants, UV-induced tolerance, and risk of non-melanoma skin cancer. Cancer Res. 2009. 69: 6158-6163.
18. Sun, T., Zhou, Y., Yang, M., Hu, Z., Tan, W., Han, X., Shi, Y. et al., Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res. 2008. 68: 7025-7034.
19. Erfani, N., Razmkhah, M., Talei, A. R., Pezeshki, A. M., Doroudchi, M., Monabati, A. and Ghaderi, A., Cytotoxic T lymphocyte antigen-4 promoter variants in breast cancer. Cancer Genet. Cytogenet. 2006. 165: 114-120.
20. Wang, L., Li, D., Fu, Z., Li, H., Jiang, W. and Li, D., Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer 2007. 7: 173.
21. Hu, J., Kindsvogel, W., Busby, S., Bailey, M. C., Shi, Y. Y. and Greenberg, P. D., An evaluation of the potential to use tumor-associated antigens as targets for antitumor T-cell therapy using transgenic mice expressing a retroviral tumor antigen in normal lymphoid tissues. J. Exp. Med. 1993. 177: 1681-1690.
22. Vierboom, M. P., Nijman, H. W., Offringa, R., van der Voort, E. I., van Hall, T., van den Broek, L., Fleuren, G. J. et al., Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J. Exp. Med. 1997. 186: 695-704.
23. Morgan, D. J., Kreuwel, H. T., Fleck, S., Levitsky, H. I., Pardoll, D. M. and Sherman, L. A., Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol. 1998. 160: 643-651.
24. Katz, J. D., Wang, B., Haskins, K., Benoist, C. and Mathis, D., Following a diabetogenic T-cell from genesis through pathogenesis. Cell 1993. 74: 1089-1100.
25. Stadinski, B. D., Delong, T., Reisdorph, N., Reisdorph, R., Powell, R. L., Armstrong, M., Piganelli, J. D. et al., Chromogranin A is an autoantigen in type 1 diabetes. Nat. Immunol. 2010. 11: 225-231.
26. Korse, C. M., Taal, B. G., Vincent, A., van Velthuysen, M. L., Baas, P., Buning-Kager, J. C., Linders, T. C. et al., Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, neuron-specific enolase, progastrin-releasing peptide and cytokeratin fragments. Eur. J. Cancer 2012. 48: 662-671.
27. Hamaguchi, K., Gaskins, H. R. and Leiter, E. H., NIT-1, a pancreatic beta-cell line established from a transgenic NOD/Lt mouse. Diabetes 1991. 40: 842-849.
28. Tirone, T. A., Fagan, S. P., Templeton, N. S., Wang, X. and Brunicardi, F. C., Insulinoma-induced hypoglycemic death in mice is prevented with beta cell-specific gene therapy. Ann. Surg. 2001. 233: 603-611.
29. + T reg cells impinge on autoimmune diabetes. J. Exp. Med. 2005. 202: 1387-1397.
30. Gabrilovich, D. I. and Nagaraj, S., Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009. 9: 162-174.
31. Kurts, C., Heath, W. R., Carbone, F. R., Allison, J., Miller, J. F. and Kosaka, H., Constitutive class I-restricted exogenous presentation of self antigens in vivo. J. Exp. Med. 1996. 184: 923-930.
32. Moore, M. W., Carbone, F. R. and Bevan, M. J., Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell 1988. 54: 777-785.
33. Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J. and Carbone, F. R., T-cell receptor antagonist peptides induce positive selection. Cell 1994. 76: 17-27.
34. Feuerer, M., Shen, Y., Littman, D. R., Benoist, C. and Mathis, D., How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets. Immunity 2009. 31: 654-664.
35. Chen, Z., Stockton, J., Mathis, D. and Benoist, C., Modeling CTLA4-linked autoimmunity with RNA interference in mice. Proc. Natl. Acad. Sci. USA 2006. 103: 16400-16405.
36. Boggio, K., Nicoletti, G., Di Carlo, E., Cavallo, F., Landuzzi, L., Melani, C., Giovarelli, M. et al., Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 1998. 188: 589-596.
37. Ambrosino, E., Spadaro, M., Iezzi, M., Curcio, C., Forni, G., Musiani, P., Wei, W. Z. et al., Immunosurveillance of Erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res. 2006. 66: 7734-7740.
38. Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008. 112: 362-373.
39. Singh, V., Ji, Q., Feigenbaum, L., Leighty, R. M. and Hurwitz, A. A., Melanoma progression despite infiltration by in vivo-primed TRP-2-specific T cells. J. Immunother. 2009. 32: 129-139.
40. + T cells. Cancer Res. 2008. 68: 2972-2983.
41. Liu, J. Q., Joshi, P. S., Wang, C., El-Omrani, H. Y., Xiao, Y., Liu, X., Hagan, J. P. et al., Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs. J. Immunol. 2010. 184: 5435-5443.
42. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. and June, C. H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011. 365: 725-733.
43. Vatakis, D. N., Koya, R. C., Nixon, C. C., Wei, L., Kim, S. G., Avancena, P., Bristol, G. et al., Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells. Proc. Natl. Acad. Sci. USA 2011. 108: E1408-E1416.
44. Pruitt, S. K., Boczkowski, D., de Rosa, N., Haley, N. R., Morse, M. A., Tyler, D. S., Dannull, J. et al., Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur. J. Immunol. 2011. 41: 3553-3563.
45. Brunkow, M. E., Jeffery, E. W., Hjerrild, K. A., Paeper, B., Clark, L. B., Yasayko, S. A., Wilkinson, J. E. et al., Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 2001. 27: 68-73.
46. Chen, Z., Benoist, C. and Mathis, D., How defects in central tolerance impinge on a deficiency in regulatory T cells. Proc. Natl. Acad. Sci. USA 2005. 102: 14735-14740.
47. Wan, Y. Y. and Flavell, R. A., Identifying Foxp3-expressing suppressor T cells with a bicistronic reporter. Proc. Natl. Acad. Sci. USA 2005. 102: 5126-5131.